JP2023508325A5 - - Google Patents
Info
- Publication number
- JP2023508325A5 JP2023508325A5 JP2022538213A JP2022538213A JP2023508325A5 JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5 JP 2022538213 A JP2022538213 A JP 2022538213A JP 2022538213 A JP2022538213 A JP 2022538213A JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- aforementioned
- product according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952114P | 2019-12-20 | 2019-12-20 | |
| US62/952,114 | 2019-12-20 | ||
| US202063009758P | 2020-04-14 | 2020-04-14 | |
| US63/009,758 | 2020-04-14 | ||
| PCT/US2020/065408 WO2021127043A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508325A JP2023508325A (ja) | 2023-03-02 |
| JP2023508325A5 true JP2023508325A5 (enExample) | 2023-12-25 |
Family
ID=76478082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538213A Pending JP2023508325A (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230053946A1 (enExample) |
| EP (1) | EP4069225A4 (enExample) |
| JP (1) | JP2023508325A (enExample) |
| KR (1) | KR20220119657A (enExample) |
| CN (1) | CN115023224A (enExample) |
| AU (1) | AU2020407572A1 (enExample) |
| BR (1) | BR112022012266A2 (enExample) |
| CA (1) | CA3165382A1 (enExample) |
| IL (1) | IL294068A (enExample) |
| MX (1) | MX2022007627A (enExample) |
| TW (1) | TW202142234A (enExample) |
| WO (1) | WO2021127043A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
| CN119524139A (zh) * | 2023-08-28 | 2025-02-28 | 海创药业股份有限公司 | 一种雌激素蛋白靶向降解剂的联合用药物及其用途 |
| WO2025096619A1 (en) * | 2023-10-30 | 2025-05-08 | The Regents Of The University Of Michigan | Dual functioning immune modulating compounds, formulations, and uses thereof |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| CN119950496B (zh) * | 2024-12-24 | 2025-11-21 | 华东师范大学 | 靶向slc7a7的抑制剂在制备治疗肺癌骨转移癌药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201607339VA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US20180002344A1 (en) * | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
-
2020
- 2020-12-16 EP EP20902430.6A patent/EP4069225A4/en active Pending
- 2020-12-16 CN CN202080095155.1A patent/CN115023224A/zh active Pending
- 2020-12-16 AU AU2020407572A patent/AU2020407572A1/en not_active Abandoned
- 2020-12-16 IL IL294068A patent/IL294068A/en unknown
- 2020-12-16 MX MX2022007627A patent/MX2022007627A/es unknown
- 2020-12-16 JP JP2022538213A patent/JP2023508325A/ja active Pending
- 2020-12-16 CA CA3165382A patent/CA3165382A1/en active Pending
- 2020-12-16 US US17/757,485 patent/US20230053946A1/en not_active Abandoned
- 2020-12-16 WO PCT/US2020/065408 patent/WO2021127043A1/en not_active Ceased
- 2020-12-16 BR BR112022012266A patent/BR112022012266A2/pt not_active IP Right Cessation
- 2020-12-16 KR KR1020227024836A patent/KR20220119657A/ko active Pending
- 2020-12-18 TW TW109145154A patent/TW202142234A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508325A5 (enExample) | ||
| JP2023507797A5 (enExample) | ||
| Roche et al. | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial | |
| Gadducci et al. | Treatment options in recurrent cervical cancer | |
| JP5424923B2 (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
| Fernandez-Pineda et al. | Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital | |
| JP2006512281A (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
| JP2019529581A5 (enExample) | ||
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| Pu et al. | A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery | |
| JP2023508327A5 (enExample) | ||
| Randall et al. | Cytoreductive surgery for ovarian cancer | |
| Curry et al. | Second-look laparotomy for ovarian cancer | |
| Howell et al. | Are aromatase inhibitors superior to antiestrogens? | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| JP2018520182A (ja) | 乳房障害を処置するための経乳頭方法及び組成物 | |
| Malik et al. | Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach? | |
| JP2023507799A5 (enExample) | ||
| Alektiar et al. | Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer | |
| Hu et al. | 5-aza-2’-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy | |
| WO2021231250A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor | |
| Bae et al. | Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B–2B cervical cancer | |
| Landreat et al. | Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases | |
| CN1630519A (zh) | 阿那曲唑用于治疗患有早期乳腺癌的绝经后的妇女的用途 | |
| Vassilomanolakis et al. | A phase II study of flutamide in ovarian cancer |